clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2022-100-2-3-85-90clinmed-356Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВлияние вируса иммунодефицита человека на костную тканьHuman immunodeficiency virus influence bone tissuehttps://orcid.org/0000-0003-4774-8588БолтенковаП. С.BoltenkovaP. S.

Болтенкова Полина Сергеевна

119991, Москва

Boltenkova Polina S.

119991 Moscow

https://orcid.org/0000-0003-2144-8595РуноваГ. Е.RunovaG. E.

Рунова Гюзель Евгеньевна — канд. мед. наук, доцент кафедры эндокринологии №1

119991, Москва

Runova Guzel E.

119991 Moscow

guzelvolkova@yandex.ruhttps://orcid.org/0000-0003-1500-1586МоргуноваТ. Б.MorgunovaT. B.

Моргунова Татьяна Борисовна — канд. мед. наук, доцент кафедры эндокриологии №1

119991, Москва

Morgunova Tatiana B.

119991 Moscow

https://orcid.org/0000-0002-3026-6315ФадеевВ. В.FadeevV. V.

Фадеев Валентин Викторович — д-р мед. наук, профессор, член-корр. РАН, заведующий кафедрой эндокринологии №1

119991, Москва

Fadeev Valentin V.

119991 Moscow

ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияFirst Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation2022240620221002-38590Copyright © Болтенкова П.С., Рунова Г.Е., Моргунова Т.Б., Фадеев В.В., 20222022Болтенкова П.С., Рунова Г.Е., Моргунова Т.Б., Фадеев В.В.Boltenkova P.S., Runova G.E., Morgunova T.B., Fadeev V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/356

Во всем мире активно изучается влияние вируса иммунодефицита человека (ВИЧ) и антиретровирусной терапии на кальциево-фосфорный обмен и минеральную плотность костной ткани. Пациенты с ВИЧ являются группой риска для снижения минеральной плотности костной ткани, поскольку данные нарушения у них встречаются чаще по сравнению со здоровыми людьми. Представлен обзор литературы, посвященный данной теме. В каждой из частей обзора рассматривается влияние ВИЧ или антиретровирусной терапии на костную ткань и остеокластогенез на разных уровнях: воздействие на молекулярном, клеточном, тканевом, гормональном уровнях, а также на уровне влияния различных внеклеточных белков. Благодаря современным диагностике и лечению выживаемость больных с ВИЧ-инфекцией значительно увеличилось, что привело к возникновению проблемы: развитию у таких пациентов заболеваний, не только связанных с нарушением иммунитета, но и появляющихся с возрастом. Говоря о нарушениях баланса остеоформирования и костной резорбции при ВИЧ-инфекции, следует учитывать многофакторность развития данных состояний для дальнейшего прогнозирования развития вторичных заболеваний, корректировки ведения пациента с учетом гормональных и возрастных изменений, распределения ресурсов, обучения врачей смежных специальностей вопросам диагностики и лечения. В обзоре используются данные рецензируемых медицинских изданий и актуальных интернет-ресурсов, включая PubMed.

The impact of human immunodeficiency virus (HIV) and antiretroviral therapy upon mineral metabolism and bone mineral density is being studied worldwide. Patients with HIV are a risk group for reduced bone mineral density as these diseases are more common in them than in healthy people. The report presents a review of the literature on the topic. The review consists of several parts, and each of them deals with the effect of HIV and antiretroviral therapy on bony tissue and osteoclastogenesis at different levels: molecular, cellular, tissue, hormonal and various extracellular protein levels. Due to modern diagnostics and treatment, the survival rate of patients with HIV infection has increased significantly. It has led to the problem of developing not only dysimmunity but also age-related diseases. When discussing the problem of bone formation and bone resorption in HIV, the multifactorial nature of these conditions must be considered to further prediction of secondary diseases development to adjust patient's management for hormonal and age-related changes, resource allocation, and educating health professionals in diagnosis and treatment. The review relies on the data from peer-reviewed medical journals, using a bibliographic search method and relevant internet resources, including PubMed.

ВИЧ-инфекцияминеральный обменостеокластогенезантиретровирусная терапияHIVmineral metabolismosteoclastogenesisantiretroviral therapyReferencesNils Venhoff, Ulrich Andreas Walker. Pathogenesis of bone disorders in HIV infection. International journal of clinical rheumatology. 2009;4(2):147–159. URL: https://www.openaccessjournals.com/articles/pathogenesis-of-bone-disorders-in-hiv-infection.pdfNils Venhoff, Ulrich Andreas Walker. Pathogenesis of bone disorders in HIV infection. International journal of clinical rheumatology. 2009;4(2):147–159. URL: https://www.openaccessjournals.com/articles/pathogenesis-of-bone-disorders-in-hiv-infection.pdfPark J.H., Lee N.K., Lee S.Y. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Mol. Cells. 2017;40(10):706–713. DOI: 10.14348/molcells.2017.0225Park J.H., Lee N.K., Lee S.Y. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Mol. Cells. 2017;40(10):706–713. DOI: 10.14348/molcells.2017.0225German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’: Human Immunodeficiency Virus (HIV)/ Transfusion medicine and hemotherapy. 2016;43(3):203–22. DOI: 10.1159/000445852German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’: Human Immunodeficiency Virus (HIV)/ Transfusion medicine and hemotherapy. 2016;43(3):203–22. DOI: 10.1159/000445852Fakruddin J.M., Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J. Biol. Chem. 2003;278(48):48251–8. DOI: 10.1074/jbc.m304676200Fakruddin J.M., Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J. Biol. Chem. 2003;278(48):48251–8. DOI: 10.1074/jbc.m304676200Planès R., Serrero M., Leghmari K., BenMohamed L., Bahraoui E. HIV-1 Envelope glycoproteins induce the production of TNF-α and IL-10 in Human monocytes by activating calcium pathway. Sci Rep. 2018;8(1):17215. DOI: 10.1038/s41598-018-35478-1Planès R., Serrero M., Leghmari K., BenMohamed L., Bahraoui E. HIV-1 Envelope glycoproteins induce the production of TNF-α and IL-10 in Human monocytes by activating calcium pathway. Sci Rep. 2018;8(1):17215. DOI: 10.1038/s41598-018-35478-1Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000;106(12):1481–8. DOI: 10.1172/jci11176Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000;106(12):1481–8. DOI: 10.1172/jci11176Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 2000;275(7):4858–64. DOI: 10.1074/jbc.275.7.4858Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 2000;275(7):4858–64. DOI: 10.1074/jbc.275.7.4858Zhao B. TNF and bone remodeling. Curr. Osteoporos. Rep. 2017;15(3):126–134. DOI: 10.1007/s11914-017-0358-zZhao B. TNF and bone remodeling. Curr. Osteoporos. Rep. 2017;15(3):126–134. DOI: 10.1007/s11914-017-0358-zKim J.M., Lin C., Stavre Z., Greenblatt M.B., Shim J.H. Osteoblast-osteoclast communication and bone homeostasis. Cells. 2020;9(9):2073. DOI: 10.3390/cells9092073Kim J.M., Lin C., Stavre Z., Greenblatt M.B., Shim J.H. Osteoblast-osteoclast communication and bone homeostasis. Cells. 2020;9(9):2073. DOI: 10.3390/cells9092073Wickramasinghe S.N., Beatty C., Shiels S., Tomlinson D.R., Harris J.R. Ultrastructure of the bone marrow in HIV infection: evidence of dyshaemopoiesis and stromal cell damage. Clinical and laboratory hematology. 1992;14(3):213–29. DOI: 10.1111/j.1365-2257.1992.tb00368.xWickramasinghe S.N., Beatty C., Shiels S., Tomlinson D.R., Harris J.R. Ultrastructure of the bone marrow in HIV infection: evidence of dyshaemopoiesis and stromal cell damage. Clinical and laboratory hematology. 1992;14(3):213–29. DOI: 10.1111/j.1365-2257.1992.tb00368.xMellert W., Kleinschmidt A., Schmidt J., Festl H., Emler S., Roth W.K., Erfl e V. Infection of human fi broblasts and osteoblast-like cells with HIV-1. AIDS. 1990;4(6):527–35. DOI: 10.1097/00002030-199006000-00006Mellert W., Kleinschmidt A., Schmidt J., Festl H., Emler S., Roth W.K., Erfl e V. Infection of human fi broblasts and osteoblast-like cells with HIV-1. AIDS. 1990;4(6):527–35. DOI: 10.1097/00002030-199006000-00006Nacher M., Serrano S., González A., Hernández A., Mariñoso M.L., Vilella R., Hinarejos P., Díez A., Aubia J. Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS. 2001;15(17):2239–43. DOI: 10.1097/00002030-200111230-00004Nacher M., Serrano S., González A., Hernández A., Mariñoso M.L., Vilella R., Hinarejos P., Díez A., Aubia J. Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS. 2001;15(17):2239–43. DOI: 10.1097/00002030-200111230-00004Kühne C.A., Heufelder A.E., Hofbauer L.C. Bone and mineral metabolism in human immunodeficiency virus infection. J. Bone Miner. Res. 2001;16(1):2–9. DOI: 10.1359/jbmr.2001.16.1.2Kühne C.A., Heufelder A.E., Hofbauer L.C. Bone and mineral metabolism in human immunodeficiency virus infection. J. Bone Miner. Res. 2001;16(1):2–9. DOI: 10.1359/jbmr.2001.16.1.2Weichold F.F., Zella D., Barabitskaja O., Maciejewski J.P., Dunn D.E., Sloand E.M., Young N.S. Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood. 1998;91(3):907–15. DOI: 10.1182/blood.V91.3.907Weichold F.F., Zella D., Barabitskaja O., Maciejewski J.P., Dunn D.E., Sloand E.M., Young N.S. Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood. 1998;91(3):907–15. DOI: 10.1182/blood.V91.3.907Chelucci C., Hassan H.J., Locardi C., Bulgarini D., Pelosi E., Mariani G., Testa U., Federico M., Valtieri M., Peschle C. In vitro human immunodeficiency virus-1 infection of purifi ed hematopoietic progenitors in single-cell culture. Blood. 1995;85(5):1181–7. DOI: 10.1182/blood.V85.5.1181.bloodjournal8551181Chelucci C., Hassan H.J., Locardi C., Bulgarini D., Pelosi E., Mariani G., Testa U., Federico M., Valtieri M., Peschle C. In vitro human immunodeficiency virus-1 infection of purifi ed hematopoietic progenitors in single-cell culture. Blood. 1995;85(5):1181–7. DOI: 10.1182/blood.V85.5.1181.bloodjournal8551181Kitano K., Abboud C.N., Ryan D.H., Quan S.G., Baldwin G.C., Golde D.W. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells. Blood. 1991;77(8):1699–705. DOI: 10.1182/blood.V77.8.1699.1699Kitano K., Abboud C.N., Ryan D.H., Quan S.G., Baldwin G.C., Golde D.W. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells. Blood. 1991;77(8):1699–705. DOI: 10.1182/blood.V77.8.1699.1699Beaupere C., Garcia M., Larghero J., Fève B., Capeau J., Lagathu C. The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation, Aging Cell. 2015;14(4):534-46. DOI: 10.1111/acel.12308Beaupere C., Garcia M., Larghero J., Fève B., Capeau J., Lagathu C. The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation, Aging Cell. 2015;14(4):534-46. DOI: 10.1111/acel.12308Serrano S., Mariñoso M.L., Soriano J.C., Rubiés-Prat J., Aubia J., Coll J., Bosch J., Del Rio L., Vila J., Goday A., Nacher., M. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 1995;16(2):185–91. DOI: 10.1016/8756-3282(94)00028-xSerrano S., Mariñoso M.L., Soriano J.C., Rubiés-Prat J., Aubia J., Coll J., Bosch J., Del Rio L., Vila J., Goday A., Nacher., M. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 1995;16(2):185–91. DOI: 10.1016/8756-3282(94)00028-xHaug C.J., Aukrust P., Haug E., Mørkrid L., Müller F., Frøland S.S. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J. Clin. Endocrinol. Metab. 1998;83(11):3832–8. DOI: 10.1210/jcem.83.11.5270Haug C.J., Aukrust P., Haug E., Mørkrid L., Müller F., Frøland S.S. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J. Clin. Endocrinol. Metab. 1998;83(11):3832–8. DOI: 10.1210/jcem.83.11.5270Díaz L., Noyola-Martínez N., Barrera D., Hernández G., Avila E., Halhali A., Larrea F. Calcitriol inhibits TNF-alpha-induced infl ammatory cytokines in human trophoblasts. J. Reprod. Immunol. 2009 Jul;81(1):17–24 DOI: 10.1016/j.jri.2009.02.005.Díaz L., Noyola-Martínez N., Barrera D., Hernández G., Avila E., Halhali A., Larrea F. Calcitriol inhibits TNF-alpha-induced infl ammatory cytokines in human trophoblasts. J. Reprod. Immunol. 2009 Jul;81(1):17–24 DOI: 10.1016/j.jri.2009.02.005.Gardner D.G., Shoback D. (Eds.) Greenspan’s Basic & Clinical Endocrinology, 10e. McGraw Hill, 2017:244. URL: https://access-medicine.mhmedical.com/content.aspx?bookid=2178&sectionid=166246461Gardner D.G., Shoback D. (Eds.) Greenspan’s Basic & Clinical Endocrinology, 10e. McGraw Hill, 2017:244. URL: https://access-medicine.mhmedical.com/content.aspx?bookid=2178&sectionid=166246461Cherqaoui R., Shakir K.M., Shokrani B., Madduri S., Farhat F., Mody V. Histopathological changes of the thyroid and parathyroid glands in HIV-infected patients. Journal of endocrinology and thyroid research. 2014;2014:364146. DOI: 10.1155/2014/364146Cherqaoui R., Shakir K.M., Shokrani B., Madduri S., Farhat F., Mody V. Histopathological changes of the thyroid and parathyroid glands in HIV-infected patients. Journal of endocrinology and thyroid research. 2014;2014:364146. DOI: 10.1155/2014/364146Wallace J.M., Hannah J.B. Pulmonary disease at autopsy in patients with the acquired immunodeficiency syndrome., West Journal of Medicine. 1988;149(2):167–71. PMID: 3266812; PMCID: PMC1026365. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1026365/pdf/westjmed00132-0037.pdfWallace J.M., Hannah J.B. Pulmonary disease at autopsy in patients with the acquired immunodeficiency syndrome., West Journal of Medicine. 1988;149(2):167–71. PMID: 3266812; PMCID: PMC1026365. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1026365/pdf/westjmed00132-0037.pdfKuehn E.W., Anders H.J., Bogner J.R., Obermaier J., Goebel F.D., Schlöndorff D. Hypocalcaemia in HIV infection and AIDS. J. Intern. Med. 1999;245(1):69–73 DOI: 10.1046/j.1365-2796.1999.00407.xKuehn E.W., Anders H.J., Bogner J.R., Obermaier J., Goebel F.D., Schlöndorff D. Hypocalcaemia in HIV infection and AIDS. J. Intern. Med. 1999;245(1):69–73 DOI: 10.1046/j.1365-2796.1999.00407.xSandhu S., Desai A., Batra M., Girdhar R., Chatterjee K., Kemp E.H., Makdissi A., Chaudhuri A. Severe symptomatic hypocalcemia from HIV related hypoparathyroidism. Case reports of endocrinology. 2018;2018:8270936. DOI: 10.1155/2018/8270936Sandhu S., Desai A., Batra M., Girdhar R., Chatterjee K., Kemp E.H., Makdissi A., Chaudhuri A. Severe symptomatic hypocalcemia from HIV related hypoparathyroidism. Case reports of endocrinology. 2018;2018:8270936. DOI: 10.1155/2018/8270936Perazella M.A., Brown E. Electrolyte and acid-base disorders associated with AIDS: an etiologic review. J. Gen. Intern. Med. 1994;9(4):232–6. DOI: 10.1007/bf02600132Perazella M.A., Brown E. Electrolyte and acid-base disorders associated with AIDS: an etiologic review. J. Gen. Intern. Med. 1994;9(4):232–6. DOI: 10.1007/bf02600132Amarnath S., Dong L., Li J., Wu Y., Chen W. Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25-T cells. Retrovirology. 2007;4:57. DOI: 10.1186/1742-4690-4-57Amarnath S., Dong L., Li J., Wu Y., Chen W. Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25-T cells. Retrovirology. 2007;4:57. DOI: 10.1186/1742-4690-4-57Contempre B., Le Moine O., Dumont J.E., Denef J.F., Many M.C. Selenium deficiency and thyroid fi brosis. A key role for macrophages and transforming growth factor beta (TGF-beta). Mol. Cell. Endocrinol. 1996;124(1–2):7–15. DOI: 10.1016/s0303-7207(96)03921-4Contempre B., Le Moine O., Dumont J.E., Denef J.F., Many M.C. Selenium deficiency and thyroid fi brosis. A key role for macrophages and transforming growth factor beta (TGF-beta). Mol. Cell. Endocrinol. 1996;124(1–2):7–15. DOI: 10.1016/s0303-7207(96)03921-4Delitala A.P., Scuteri A., Doria C. Thyroid hormone diseases and osteoporosis. J .Сlin. med. 2020;9(4):1034. DOI: 10.3390/jcm9041034Delitala A.P., Scuteri A., Doria C. Thyroid hormone diseases and osteoporosis. J .Сlin. med. 2020;9(4):1034. DOI: 10.3390/jcm9041034Ночевная Л.Б., Павленко О.А., Килина О.Ю., Столярова В.А. Состояние костной ткани у пациентов с впервые выявленным гипотиреозом. Сибирский журнал клинической и экспериментальной медицины. 2011;26(4–2):189–193.Nochevnaja L.B., Pavlenko O.A., Kilina O.Ju., Stoljarova V.A.: The state of bone tissue in patients with new onset hypothyroidism, Sibirskij zhurnal klinicheskoj i jeksperimental'noj mediciny. 2011;26(4–2):189–193. (In Russian)Wong N., Levy M., Stephenson I.: Hypogonadism in the HIV-infected man. Current treatment options in infectious diseases. 2017;9(1):104–116. DOI: 10.1007/s40506-017-0110-3Wong N., Levy M., Stephenson I.: Hypogonadism in the HIV-infected man. Current treatment options in infectious diseases. 2017;9(1):104–116. DOI: 10.1007/s40506-017-0110-3Golds G., Houdek D., Arnason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. International journal of endocrinology. 2017;2017:4602129. DOI: 10.1155/2017/4602129Golds G., Houdek D., Arnason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. International journal of endocrinology. 2017;2017:4602129. DOI: 10.1155/2017/4602129Sinha U., Sengupta N., Mukhopadhyay P., Roy K.S. Human immunodeficiency virus endocrinopathy. Indian journal of endocrinology and metabolism. 2011;15(4):251–60. DOI: 10.4103/2230-8210.85574Sinha U., Sengupta N., Mukhopadhyay P., Roy K.S. Human immunodeficiency virus endocrinopathy. Indian journal of endocrinology and metabolism. 2011;15(4):251–60. DOI: 10.4103/2230-8210.85574Almeida M., Laurent M.R., Dubois V., Claessens F., O'Brien C.A., Bouillon R., Vanderschueren D., Manolagas S.C. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol. Rev. 2017;97(1):135–187. DOI: 10.1152/physrev.00033.2015Almeida M., Laurent M.R., Dubois V., Claessens F., O'Brien C.A., Bouillon R., Vanderschueren D., Manolagas S.C. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol. Rev. 2017;97(1):135–187. DOI: 10.1152/physrev.00033.2015Siddiqui J., Phillips A.L., Freedland E.S., Sklar A.R., Darkow T., Harley C.R. Prevalence and cost of HIV-associated weight loss in a managed care population. Curr. Med. Res. Opin. 2009;25(5):1307–17. DOI: 10.1185/03007990902902119Siddiqui J., Phillips A.L., Freedland E.S., Sklar A.R., Darkow T., Harley C.R. Prevalence and cost of HIV-associated weight loss in a managed care population. Curr. Med. Res. Opin. 2009;25(5):1307–17. DOI: 10.1185/03007990902902119Reiter G.S. The HIV wasting syndrome. AIDS clinical care. 1996;8(11):89–91,93,96. PMID: 11363990.Reiter G.S. The HIV wasting syndrome. AIDS clinical care. 1996;8(11):89–91,93,96. PMID: 11363990.Christian Hoffmann, Jürgen K. Rockstroh, ed. VICh 2014/2015 [HIV 2014/2015]. Hamburg; Bonn; 2014:942. URL: http://www.hivbuch.de (accessed: 20.05.2019)Christian Hoffmann, Jürgen K. Rockstroh, ed. VICh 2014/2015 [HIV 2014/2015]. Hamburg; Bonn; 2014:942. URL: http://www.hivbuch.de (accessed: 20.05.2019)Conesa-Buendía F.M., Llamas-Granda P., Larrañaga-Vera A., Wilder T., Largo R., Herrero-Beaumont G., Cronstein B., Mediero A. Tenofovir causes bone loss via decreased bone formation and increased bone resorption, which can be counteracted by dipyridamole in mice. J. Bone Miner. Res. 2019;34(5):923–938. DOI: 10.1002/jbmr.3665Conesa-Buendía F.M., Llamas-Granda P., Larrañaga-Vera A., Wilder T., Largo R., Herrero-Beaumont G., Cronstein B., Mediero A. Tenofovir causes bone loss via decreased bone formation and increased bone resorption, which can be counteracted by dipyridamole in mice. J. Bone Miner. Res. 2019;34(5):923–938. DOI: 10.1002/jbmr.3665Haskelberg H., Hoy J.F., Amin J., Ebeling P.R., Emery S., Carr A. STEAL Study Group. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One. 2012;7(6):e38377. DOI: 10.1371/journal.pone.0038377Haskelberg H., Hoy J.F., Amin J., Ebeling P.R., Emery S., Carr A. STEAL Study Group. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One. 2012;7(6):e38377. DOI: 10.1371/journal.pone.0038377Pan G., Wu X., McKenna M.A., Feng X., Nagy T.R., McDonald J.M. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20(6):608–20. DOI: 10.1089/0889222041217482Pan G., Wu X., McKenna M.A., Feng X., Nagy T.R., McDonald J.M. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20(6):608–20. DOI: 10.1089/0889222041217482Pan G., Yang Z., Ballinger S.W., McDonald J.M. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann. N.-Y. Acad. Sci. 2006;1068:297–308. DOI: 10.1196/annals.1346.057Pan G., Yang Z., Ballinger S.W., McDonald J.M. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann. N.-Y. Acad. Sci. 2006;1068:297–308. DOI: 10.1196/annals.1346.057Lucey J.M., Hsu P., Ziegler J.B. Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV. BMJ Case Rep. 2013;2013:bcr2013008674. DOI: 10.1136/bcr-2013-008674Lucey J.M., Hsu P., Ziegler J.B. Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV. BMJ Case Rep. 2013;2013:bcr2013008674. DOI: 10.1136/bcr-2013-008674Overton E.T., Chan E.S., Brown T.T., Tebas P., McComsey G.A., Melbourne K.M., Napoli A., Hardin W.R., Ribaudo H.J., Yin M.T. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann. Intern. Med. 2015;162(12):815–24. DOI: 10.7326/m14-1409Overton E.T., Chan E.S., Brown T.T., Tebas P., McComsey G.A., Melbourne K.M., Napoli A., Hardin W.R., Ribaudo H.J., Yin M.T. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann. Intern. Med. 2015;162(12):815–24. DOI: 10.7326/m14-1409Moran C.A., Weitzmann M.N, Ofotokun I.: The protease inhibitors and HIV-associated bone loss. Curr. Opin. HIV AIDS. 2016;11(3):333–42. DOI: 10.1097/coh.0000000000000260Moran C.A., Weitzmann M.N, Ofotokun I.: The protease inhibitors and HIV-associated bone loss. Curr. Opin. HIV AIDS. 2016;11(3):333–42. DOI: 10.1097/coh.0000000000000260Hernandez-Vallejo S.J., Beaupere C., Larghero J., Capeau J., Lagathu C. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: benefi cial effect of pravastatin. Aging Cell. 2013;12(6):955–65. DOI: 10.1111/acel.12119Hernandez-Vallejo S.J., Beaupere C., Larghero J., Capeau J., Lagathu C. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: benefi cial effect of pravastatin. Aging Cell. 2013;12(6):955–65. DOI: 10.1111/acel.12119Cozzolino M., Vidal M., Arcidiacono M.V., Tebas P., Yarasheski K.E., Dusso A.S. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–20. DOI: 10.1097/00002030-200303070-00006Cozzolino M., Vidal M., Arcidiacono M.V., Tebas P., Yarasheski K.E., Dusso A.S. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–20. DOI: 10.1097/00002030-200303070-00006Soldado-Folgado J., Lerma-Chippirraz E., Arrieta-Aldea I., Bujosa D., García-Giralt N., Pineda-Moncusi M., Trenchs-Rodríguez M., Villar-García J., González-Mena A., Díez-Pérez A., Brown T.T., Knobel H., Güerri-Fernández R. Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine. J. Antimicrob. Chemother. 2020;75(10):2998–3003. DOI: 10.1093/jac/dkaa254Soldado-Folgado J., Lerma-Chippirraz E., Arrieta-Aldea I., Bujosa D., García-Giralt N., Pineda-Moncusi M., Trenchs-Rodríguez M., Villar-García J., González-Mena A., Díez-Pérez A., Brown T.T., Knobel H., Güerri-Fernández R. Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine. J. Antimicrob. Chemother. 2020;75(10):2998–3003. DOI: 10.1093/jac/dkaa254Mundy LM., Youk AO., McComsey GA., Bowlin SJ.: Overall benefi t of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS. 2012 Jun 1;26(9):1073-82. DOI: 10.1097/qad.0b013e328351997fMundy LM., Youk AO., McComsey GA., Bowlin SJ.: Overall benefi t of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS. 2012 Jun 1;26(9):1073-82. DOI: 10.1097/qad.0b013e328351997fTaiwo B.O., Chan ES., Fichtenbaum C.J., Ribaudo H., Tsibris A., Klingman K.L., Eron J.J., Berzins B., Robertson K., Landay A., Ofotokun I., Brown T. AIDS Clinical trials group A5303 Study Team. Less bone loss with maravirocversus tenofovir-containing antiretroviral therapy in the AIDS Clinical trials group A5303 Study. Clin. Infect. Dis. 2015;61(7):1179–88. DOI: 10.1093/cid/civ455Taiwo B.O., Chan ES., Fichtenbaum C.J., Ribaudo H., Tsibris A., Klingman K.L., Eron J.J., Berzins B., Robertson K., Landay A., Ofotokun I., Brown T. AIDS Clinical trials group A5303 Study Team. Less bone loss with maravirocversus tenofovir-containing antiretroviral therapy in the AIDS Clinical trials group A5303 Study. Clin. Infect. Dis. 2015;61(7):1179–88. DOI: 10.1093/cid/civ455EACS Guidelines version 10.1, October 2020. URL: https://www.eacsociety.org/media/eacs_gudelines_2019_rus.pdfEACS Guidelines version 10.1, October 2020. URL: https://www.eacsociety.org/media/eacs_gudelines_2019_rus.pdf

The authors declare that there are no conflicts of interest present.